KLRG1 and neoplasm: Administration of a bromodomain inhibitor also partially depleted intratumoral Tregs, and when this treatment is combined with anti-KLRG1 antibody, tumor-infiltrating CD8+ T-cells express higher levels of granzyme B and IFN-γ, significantly improving the antitumor response [25].